GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenyn Biotechnology Co Ltd (ROCO:6846) » Definitions » Current Deferred Revenue

Greenyn Biotechnology Co (ROCO:6846) Current Deferred Revenue : NT$0.0 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Greenyn Biotechnology Co Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Greenyn Biotechnology Co's current deferred revenue for the quarter that ended in Mar. 2024 was NT$0.0 Mil.

Greenyn Biotechnology Co Current Deferred Revenue Historical Data

The historical data trend for Greenyn Biotechnology Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenyn Biotechnology Co Current Deferred Revenue Chart

Greenyn Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
- - - - -

Greenyn Biotechnology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Greenyn Biotechnology Co Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Greenyn Biotechnology Co's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenyn Biotechnology Co (ROCO:6846) Business Description

Traded in Other Exchanges
N/A
Address
5th Floor, No 43 Keya Road, Daya District, Taichung, TWN
Greenyn Biotechnology Co Ltd has developed Insumate patented sequenced peptide, Antromax Antrodia cinnamomea mycelia, and Zymologist fermented liquid.

Greenyn Biotechnology Co (ROCO:6846) Headlines

No Headlines